1. Home
  2. TMDX vs RPD Comparison

TMDX vs RPD Comparison

Compare TMDX & RPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMDX
  • RPD
  • Stock Information
  • Founded
  • TMDX 1998
  • RPD 2000
  • Country
  • TMDX United States
  • RPD United States
  • Employees
  • TMDX N/A
  • RPD N/A
  • Industry
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • RPD Computer Software: Prepackaged Software
  • Sector
  • TMDX Health Care
  • RPD Technology
  • Exchange
  • TMDX Nasdaq
  • RPD Nasdaq
  • Market Cap
  • TMDX 2.1B
  • RPD 2.4B
  • IPO Year
  • TMDX 2019
  • RPD 2015
  • Fundamental
  • Price
  • TMDX $57.20
  • RPD $38.84
  • Analyst Decision
  • TMDX Buy
  • RPD Buy
  • Analyst Count
  • TMDX 11
  • RPD 18
  • Target Price
  • TMDX $116.10
  • RPD $44.71
  • AVG Volume (30 Days)
  • TMDX 2.6M
  • RPD 671.1K
  • Earning Date
  • TMDX 02-24-2025
  • RPD 02-12-2025
  • Dividend Yield
  • TMDX N/A
  • RPD N/A
  • EPS Growth
  • TMDX N/A
  • RPD N/A
  • EPS
  • TMDX 0.94
  • RPD 0.66
  • Revenue
  • TMDX $401,090,000.00
  • RPD $833,014,000.00
  • Revenue This Year
  • TMDX $81.61
  • RPD $9.10
  • Revenue Next Year
  • TMDX $22.52
  • RPD $5.35
  • P/E Ratio
  • TMDX $61.04
  • RPD $59.12
  • Revenue Growth
  • TMDX 109.09
  • RPD 10.05
  • 52 Week Low
  • TMDX $56.03
  • RPD $32.95
  • 52 Week High
  • TMDX $177.37
  • RPD $61.88
  • Technical
  • Relative Strength Index (RSI)
  • TMDX 35.74
  • RPD 42.30
  • Support Level
  • TMDX $58.40
  • RPD $37.57
  • Resistance Level
  • TMDX $67.80
  • RPD $40.42
  • Average True Range (ATR)
  • TMDX 4.59
  • RPD 1.20
  • MACD
  • TMDX -0.27
  • RPD 0.00
  • Stochastic Oscillator
  • TMDX 4.44
  • RPD 33.33

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

Share on Social Networks: